GAITHERSBURG, MD--(Marketwire - April 14, 2011) -
Noble Life Sciences announced today the appointment of Stephen Horrigan, PhD, as the company's Chief Scientific Officer.
"We are delighted that Dr. Horrigan has joined our team. Steve is an accomplished molecular geneticist who is known for his contributions to the development of innovative approaches for using genomic profiles and biomarkers to enhance drug discovery and development," said Dr. Kenneth Carter, President and CEO of Noble Life Sciences. "Dr. Horrigan has strong expertise in cellular control mechanisms of cancer and the use of biomarkers for discovery and development of therapeutics. He will be invaluable in providing biomarker validation services and guidance on pre-clinical drug development to our clients."
Prior to joining Noble, Dr. Horrigan was the Vice President of Research at Avalon Pharmaceuticals, a wholly-owned subsidiary of Clinical Data, Inc. During his tenure at Avalon, he held several positions of increasing responsibility within the research organization while directing both internal and collaborative research programs. He also played a key leadership role in the development of the company's unique genomic biomarker-driven R&D platform. Prior to joining Avalon, Dr. Horrigan was Associate Professor in the Department of Pediatrics and Lombardi Cancer Center at Georgetown University Medical Center where he led a research group focused on cancer genomics and the application of biomarkers in cancer diagnostics. He has also held positions at the University of Illinois College of Medicine and the University of Chicago School of Medicine.
At the same time, Noble announced the appointment of Jeffrey W. Strovel, PhD, as the Vice President, Translational Medicine. Previously, Dr. Strovel was the Head of Discovery Research at Avalon Pharmaceuticals where he was instrumental in developing many of the company's novel biomarker-driven discovery systems. At Avalon, Dr. Strovel also led discovery efforts which resulted in the identification of the company's seminal product development candidate, a mechanistically novel cancer drug candidate targeting a major, previously intractable, target pathway in colorectal cancer. Earlier in his career, Dr. Strovel held positions at the University of Maryland and the National Cancer Institute.
Noble Life Sciences also announced the appointment of Stephen J. Garvey, LATg, as Vice President, Laboratory Resources and Services. For eight years prior to the inception of Noble, Mr. Garvey oversaw vivarium services at Avalon Pharmaceuticals and managed research contracts for housing and husbandry clients. He also has held positions at Human Genome Sciences, GlaxoSmithKline, and the Philadelphia College of Osteopathic Medicine.
About Noble Life Sciences:
Noble Life Sciences provides a continuum of preclinical research services including preclinical experimental design and testing, disease models, selection and validation of biomarkers for personalized medicine, and vivarium services. With deep expertise in cancer drug development, the company offers access to their top scientists and works collaboratively with researchers in pharmaceutical, biotechnology, and diagnostic companies as well as those in academic and government institutions to deliver relevant, actionable information needed to expedite preclinical research and guide clinical development. For more information about Noble Life Sciences, visit www.noblelifesci.com.